Inventiva (IVA) to Release Quarterly Earnings on Thursday

Key Points

• Inventiva (NASDAQ:IVA) is set to release its Q2 2025 earnings on September 25th, with analysts projecting an earnings per share loss of ($0.41).
• Recent analyst ratings for Inventiva include a buy rating from HC Wainwright with a $20.00 target price and an upgrade by Guggenheim lifting its price objective to $13.00.
• Institutional ownership of Inventiva stands at 19.06%, with Creative Planning recently acquiring 10,000 shares valued around $32,000.

Inventiva (NASDAQ:IVA - Get Free Report) will likely be issuing its Q2 2025 results before the market opens on Thursday, September 25th. Analysts expect the company to announce earnings of ($0.41) per share for the quarter. Parties may visit the the company's upcoming Q2 2025 earningresults page for the latest details on the call scheduled for Monday, September 29, 2025 at 11:40 AM ET.

Inventiva Price Performance

Shares of NASDAQ:IVA opened at $5.28 on Thursday. The company's 50 day moving average is $4.27 and its two-hundred day moving average is $3.60. Inventiva has a 52 week low of $1.53 and a 52 week high of $6.50.

Analyst Ratings Changes

Several analysts have recently commented on IVA shares. HC Wainwright initiated coverage on shares of Inventiva in a research note on Wednesday, September 3rd. They issued a "buy" rating and a $20.00 target price for the company. Piper Sandler started coverage on shares of Inventiva in a research report on Wednesday, August 27th. They set an "overweight" rating and a $26.00 target price for the company. Finally, Guggenheim boosted their price objective on shares of Inventiva from $9.00 to $13.00 and gave the company a "buy" rating in a research report on Tuesday, September 2nd. Five research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat, Inventiva presently has a consensus rating of "Moderate Buy" and a consensus price target of $14.83.

Hedge Funds Weigh In On Inventiva

A hedge fund recently bought a new stake in Inventiva stock. Creative Planning bought a new position in Inventiva S.A. Sponsored ADR (NASDAQ:IVA - Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 10,000 shares of the company's stock, valued at approximately $32,000. Institutional investors own 19.06% of the company's stock.

About Inventiva

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.